Profile

William T. Lowther, Ph.D.Wake Forest School of Medicine

William T. Lowther, Ph.D.

Associate Professor,

Contact Information

Academic: 336-716-4373 | Department: 336-716-7230

Email: tlowther@wakehealth.edu

Education & Training

  • B.S., Stetson University, 1989
  • Ph.D., University of Florida, 1994
  • Fellowship, Molecular Biology, University of Florida College, 2002

Memberships

  • Am Chemical Society
  • American Crystallographic Asso
  • Am Soc Of Biochem & Mol Biolog
William T. Lowther, Ph.D.

William T. Lowther, Ph.D.

Associate Professor, Biochemistry

Contact Information

Academic: 336-716-4373 | Department: 336-716-7230

Email: tlowther@wakehealth.edu

Recent Publications

Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP.. Biochim Biophys Acta. 2016;1862(2):233-239.

Crystal structure and substrate specificity of human thioesterase 2: insights into the molecular basis for the modulation of fatty acid synthase. Ritchie MK, Johnson LC, Clodfelter JE, Pemble CW IV, Fulp BE, Furdui CM, Kridel SJ, Lowther WT.. J Biol Chem. 2016;291(7):3520-3530.

Development of a self-assembled nanoparticle formulation of Orlistat, Nano-ORL, with increased cytotoxicity against human tumor cell lines. Hill TK, Davis AL, Wheeler FB, Kelkar SS, Freund EC, Lowther WT, Kridel SJ, Mohs AM.. Mol Pharm. 2016;13(3):720-728.

Kinetic analysis of structural influences on the susceptibility of peroxiredoxins 2 and 3 to hyperoxidation. Poynton RA, Peskin AV, Haynes AC, Lowther WT, Hampton MB, Winterbourn CC.. Biochem J. 2016;473(4):411-421.

Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria. Summitt CB, Johnson LC, Jonsson TJ, Parsonage D, Holmes RP, Lowther WT.. Biochem J. 2015;466(2):273-281.

Disabling mitochondrial peroxide metabolism via combinatorial targeting of peroxiredoxin 3 as an effective therapeutic approach for malignant mesothelioma. Cunniff B, Newick K, Nelson KJ, Wozniak AN, Beuschel S, Leavitt B, Bhave A, Butnor K, Koenig A, Chouchani ET, James AM, Haynes AC, Lowther WT, Murphy MP, Shukla A, Heintz NH.. PLoS One. 2015;10(5):e0127310.

Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3. Li X, Knight J, Todd Lowther W, Holmes RP.. Biochim Biophys Acta. 2015;1852(12):2700-2705.

Determining the molecular basis for differential hyperoxidation sensitivity in peroxiredoxin 1 & 2 [abstract]. Bolduc J, Reisz-Haines J, Nelson K, Furdui C, Lowther WT.. FASEB J. 2015;29(Suppl 1):895.10.

Expression and purification of integral membrane fatty acid desaturases. Chen H, Gu Z, Zhang H, Wang M, Chen W, Lowther WT, Chen YQ.. PLoS One. 2013;8(3):e58139.

Molecular basis for the resistance of human mitochondrial 2-Cys peroxiredoxin 3 to hyperoxidation. Haynes AC, Qian J, Reisz JA, Furdui CM, Lowther WT.. J Biol Chem. 2013;288(41):29714-23.

Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria. Jiang J, Johnson LC, Knight J, Callahan MF, Riedel TJ, Holmes RP, Lowther WT.. Am J Physiol Gastrointest Liver Physiol. 2012;302(6):G637-G643.

Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. Lema Tome CM, Palma E, Ferlaga S, Lowther WT, Hantgan R, Wykosky J, Debinski W.. J Biol Chem. 2012;287(17):14012-22.

4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT.. Biochim Biophys Acta. 2012;1822(10):1544-1552.

Reduction of cysteine sulfinic acid in eukaryotic, typical 2-Cys peroxiredoxins by sulfiredoxin. Lowther WT, Haynes AC.. Antioxid Redox Signal. 2011;15(1):99-109.

Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluria. Riedel TJ, Johnson LC, Knight J, Hantgan RR, Holmes RP, Lowther WT.. PLoS ONE. 2011;6(10):e26021.

Use of dimedone-based chemical probes for sulfenic acid detection evaluation of conditions affecting probe incorporation into redox-sensitive proteins. Klomsiri C, Nelson KJ, Bechtold E, Soito L, Johnson LC, Lowther WT, Ryu S-E, King SB, Furdui CM, Poole LB.. Methods Enzymol. 2010;473():77-94.

Mitochondrial peroxiredoxin 3 is more resilient to hyperoxidation than cytoplasmic peroxiredoxins. Cox AG, Pearson AG, Pullar JM, Jonsson TJ, Lowther WT, Winterbourn CC, Hampton MB.. Biochem J. 2009;421(1):51-58.

Protein engineering of the quaternary sulfiredoxin.peroxiredoxin enzyme.substrate complex reveals the molecular basis for cysteine sulfinic acid phosphorylation. Jonsson TJ, Johnson LC, Lowther WT.. J Biol Chem. 2009;284(48):33305-10.

Structure of the sulphiredoxin-peroxiredoxin complex reveals an essential repair embrace. Jonsson TJ, Johnson LC, Lowther WT.. Nature. 2008;451(7174):98-101.

Active site and loop 4 movements within human glycolate oxidase: implications for substrate specificity and drug design. Murray MS, Holmes RP, Lowther WT.. Biochemistry. 2008;47(8):2439-2449.

Identification of intact protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin. Jonsson TJ, Tsang AW, Lowther WT, Furdui CM.. J Biol Chem. 2008;283(34):22890-94.

Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate. Jonsson TJ, Murray MS, Johnson LC, Lowther WT.. J Biol Chem. 2008;283(35):23846-51.

A disulfide intermediate is required for the reduction of methionine sulfoxide reductase by thioredoxin [abstract]. Brunell DJ, Lowther T, Sagher D, Brot N, Weissbach H.. FASEB J. 2007;21(5):A275.

Free methionine-(R)-sulfoxide reductase from Escherichia coli reveals a new GAF domain function. Lin Z, Johnson LC, Weissbach H, Brot N, Lively MO, Lowther WT.. Proc Natl Acad Sci U S A. 2007;104(23):9597-9602.

Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Pemble CW IV, Johnson LC, Kridel SJ, Lowther WT.. Nat Struct Mol Biol. 2007;14(8):704-709.

Fatty acid synthase inhibitors: new directions for oncology. Kridel SJ, Lowther WT, Pemble CW IV.. Expert Opin Investig Drugs. 2007;16(11):1817-1829.

The peroxiredoxin repair proteins. Jonsson TJ, Lowther WT.. Subcell Biochem. 2007;44():115-141.

Structure of the sulfiredoxin-peroxiredoxin complex reveals basis for cysteine sulfinic acid repair [abstract]. Jonsson TJ, Johnson LC, Lowther WT.. Free Radic Biol Med. 2007;43(Suppl 1):S110.

The thioredoxin domain of Neisseria gonorrhoeae PilB can use electrons from DsbD to reduce downstream methionine sulfoxide reductases. Brot N, Collet J-F, Johnson LC, Jonsson TJ, Weissbach H, Lowther WT.. J Biol Chem. 2006;281(43):32668-75.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Biochemistry

William T. Lowther, Ph.D.

William T. Lowther, Ph.D.

Associate Professor, Biochemistry

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.